title: Mometasone furoate dry powder inhaler for the treatment of asthma.
abstract: BACKGROUND
  Asthma is a chronic inflammatory disease that causes significant morbidity and mortality. Inhaled corticosteroids are the preferred initial treatment for this disorder. Mometasone furoate dry powder is an inhaled corticosteroid that is approved for once-daily treatment of asthma in both adults and children as young as 4 years.
  
  
  METHODS
  The goal of this paper is to review the clinical efficacy and safety of mometasone furoate dry powder inhaler for the treatment of asthma. A literature search using PubMed was done using the terms 'mometasone furoate', 'inhaled corticosteroid' and 'asthma', focusing on articles that highlighted clinical trials and addressed efficacy of the medication.
  
  
  CONCLUSIONS
  Mometasone furoate dry powder inhaler has an excellent safety and efficacy profile. For patients with persistent asthma who require treatment with an inhaled corticosteroid, mometasone furoate is an excellent therapeutic choice.
authors: Penn State Hershey Medical Center, Penn State College of Medicine - Pediatrics, Section of Allergy and Immunology, 500 University Drive, Hershey, PA 17033, USA. tfausnight@hmc.psu.edu
authors: Tracy B
authors: TB
authors: Fausnight
authors: Timothy J
authors: TJ
authors: Craig
mesh_terms: D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D058995:Dry Powder Inhalers; D006801:Humans; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000494:pharmacology / Q000627:therapeutic use*; D011788:Quality of Life
chemical_list: D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate